Efficacy of 99mTc-sestamibi SPECT/CT for minimally invasive parathyroidectomy: comparative study with 99mTc-sestamibi scintigraphy, SPECT, US and CT
Authors:
- 9 August 2012
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 26 (10) , 804-810
Abstract
We evaluated the efficacy of 99mTc-sestamibi SPECT/CT for planning minimally invasive parathyroidectomy (MIP), comparing with dual phase 99mTc-sestamibi scintigraphy, 99mTc-sestamibi SPECT and conventional imaging (US and CT). Thirty-one patients (M:F = 10:21, range 35–78 years old) who showed high serum parathyroid hormone (intact PTH) level were included. 99mTc-sestamibi scintigraphy was performed 15 and 150 min after injection of 99mTc-sestamibi (555 MBq), and 99mTc-sestamibi SPECT/CT was obtained just after the delayed scan. Comparison study between imaging modalities was done by patient-based and lesion location-based analysis. The location of the lesion was confirmed by the operative finding. An operation was performed in 24 patients. Seven patients had normal 99mTc-sestamibi SPECT/CT, and followed for more than 6 months after SPECT/CT. Among 24 patients, parathyroid adenoma was detected in 19 patients and the other 5 had parathyroid hyperplasia (total 35 lesions). 99mTc-sestamibi scintigraphy detected abnormal uptake in 15 patients with 24 lesions. Conventional imaging identified abnormal findings in 17 patients with 27 lesions. SPECT detected abnormal findings in 18 patients with 27 lesions. SPECT/CT identified abnormal findings in 24 patients with 35 lesions. SPECT/CT demonstrated 100 % sensitivity in a patient-based analysis. SPECT/CT exhibited significantly better sensitivity than 99mTc-sestamibi scintigraphy, SPECT and conventional imaging (p < 0.05). All lesion location was correctly identified to perform MIP. The final clinical diagnosis of 7 normal SPECT/CT patients was secondary hyperparathyroidism on 6 months follow-up. We correctly identified the precise location of parathyroid adenomas or hyperplasia by 99mTc-sestamibi SPECT/CT which was helpful to perform MIP.Keywords
This publication has 28 references indexed in Scilit:
- Can Ultrasound Be Used as the Primary Screening Modality for the Localization of Parathyroid Disease prior to Surgery for Primary Hyperparathyroidism? A Review of 440 CasesORL, 2011
- Contraindications to magnetic resonance imagingHeart, 2008
- Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imagingAnnals of Nuclear Medicine, 2008
- Scintigraphic techniques in primary hyperparathyroidism: from pre-operative localisation to intra-operative imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Technetium‐99m‐MIBI SPECT/CT in Primary HyperparathyroidismWorld Journal of Surgery, 2005
- A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003Otolaryngology–Head and Neck Surgery, 2005
- Imaging for primary hyperparathyroidism — what beginners should knowClinical Radiology, 2004
- In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondriaSurgery, 2001
- Thyroid and parathyroid imagingSeminars in Ultrasound, CT and MRI, 1995
- Pre-operative localisation in primary hyperparathyroidismClinical Radiology, 1990